141 related articles for article (PubMed ID: 37724232)
1. Clinical Features and Prognostic Factors in Patients With Uterine Leiomyosarcoma: A Single-Center Experience.
Yalciner M; Bölek H; Berna Köksoy E
Cureus; 2023 Aug; 15(8):e43681. PubMed ID: 37724232
[TBL] [Abstract][Full Text] [Related]
2. Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma.
Giuntoli RL; Lessard-Anderson CR; Gerardi MA; Kushnir CL; Cliby WA; Metzinger DS; Gostout BS
Int J Gynecol Cancer; 2013 Jun; 23(5):869-76. PubMed ID: 23669444
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and survival in patients treated surgically for primary and recurrent uterine leiomyosarcoma: a single center experience.
Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
Anticancer Res; 2015 Apr; 35(4):2229-34. PubMed ID: 25862883
[TBL] [Abstract][Full Text] [Related]
4. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
5. "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas.
Veras E; Zivanovic O; Jacks L; Chiappetta D; Hensley M; Soslow R
Am J Surg Pathol; 2011 Nov; 35(11):1626-37. PubMed ID: 21921786
[TBL] [Abstract][Full Text] [Related]
6. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems.
Zivanovic O; Leitao MM; Iasonos A; Jacks LM; Zhou Q; Abu-Rustum NR; Soslow RA; Juretzka MM; Chi DS; Barakat RR; Brennan MF; Hensley ML
J Clin Oncol; 2009 Apr; 27(12):2066-72. PubMed ID: 19255317
[TBL] [Abstract][Full Text] [Related]
7. Clinical Characteristics, Surgical Management and Adjuvant Therapy of Patients with Uterine Leiomyosarcoma: 27 Years of Experience.
Rothmund R; Huebner M; Joachim C; Hartkopf A; Fehm T; Bamberg M; Wallwiener M; Brucker S; Taran FA
Geburtshilfe Frauenheilkd; 2011 Dec; 71(12):1085-1089. PubMed ID: 27065481
[No Abstract] [Full Text] [Related]
8. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and outcomes in 28 cases of uterine leiomyosarcoma.
Loizzi V; Cormio G; Nestola D; Falagario M; Surgo A; Camporeale A; Putignano G; Selvaggi L
Oncology; 2011; 81(2):91-7. PubMed ID: 21968290
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors, oncological treatment and outcomes of uterine sarcoma: 10 years' clinical experience from a tertiary care center in Pakistan.
Khan SR; Soomar SM; Asghari T; Ahmed A; Moosajee MS
BMC Cancer; 2023 Jun; 23(1):510. PubMed ID: 37277708
[TBL] [Abstract][Full Text] [Related]
12. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?
Ricci S; Giuntoli RL; Eisenhauer E; Lopez MA; Krill L; Tanner EJ; Gehrig PA; Havrilesky LJ; Secord AA; Levinson K; Frasure H; Celano P; Fader AN
Gynecol Oncol; 2013 Dec; 131(3):629-33. PubMed ID: 24016408
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic analysis of stage Ⅰb2 andⅡa2 cervical squamous cancer without high risk factors treated with neo-adjuvant chemotherapy and radical hysterectomy].
Li PP; Li B; Wang YT; Liu SH; Zhang YN; Zhang R; Bai P; Li XG; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2018 Apr; 53(4):248-256. PubMed ID: 29747270
[No Abstract] [Full Text] [Related]
14. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma.
Zivanovic O; Jacks LM; Iasonos A; Leitao MM; Soslow RA; Veras E; Chi DS; Abu-Rustum NR; Barakat RR; Brennan MF; Hensley ML
Cancer; 2012 Feb; 118(3):660-9. PubMed ID: 21751199
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and prognosis analysis of uterine sarcoma: a single-institution retrospective study.
Wang F; Dai X; Chen H; Hu X; Wang Y
BMC Cancer; 2022 Oct; 22(1):1050. PubMed ID: 36207687
[TBL] [Abstract][Full Text] [Related]
16. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and treatment outcomes in 93 patients with uterine sarcoma from 4 centers in Turkey.
Durnali A; Tokluoğlu S; Özdemir N; Inanç M; Alkiş N; Zengin N; Sönmez ÖU; Küçüköner M;
Asian Pac J Cancer Prev; 2012; 13(5):1935-41. PubMed ID: 22901150
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in early-stage leiomyosarcoma of the uterus.
Pelmus M; Penault-Llorca F; Guillou L; Collin F; Bertrand G; Trassard M; Leroux A; Floquet A; Stoeckle E; Thomas L; MacGrogan G
Int J Gynecol Cancer; 2009 Apr; 19(3):385-90. PubMed ID: 19407564
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: A Korean multicenter study.
Kim SI; Choi CH; Kim K; Hong DH; Park JY; Kwon BS; Lee KH; Hong DG; Shin SJ; Park SI; Kim YH; Lee SH; Lee S; Hong JH; Lee JY; Kim YB; No JH; Suh DH
J Obstet Gynaecol Res; 2020 Feb; 46(2):337-346. PubMed ID: 31814199
[TBL] [Abstract][Full Text] [Related]
20. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
